PlainMeds provides educational information only. This is not medical advice. Always consult your doctor or pharmacist.

Drug side effects

colestipol Side Effects

The reactions most often reported to the FDA for colestipol (also sold as Colestid), with demographics, serious outcomes, and reporting trends.

Data updated 2026-05-15

2,477
FAERS reports

Data from the FDA Adverse Event Reporting System (FAERS), 2004 to 2025. A FAERS report records a temporal association, not proof of cause. See our methodology for how figures are compiled and de-duplicated.

The most commonly reported side effects of colestipol come from 2,477 reports to the FDA, broken down here by frequency, patient demographics, and serious outcomes.

This page analyzes 2,477 reports to the FDA Adverse Event Reporting System (FAERS) for colestipol (Colestid): the reactions reported most often, who reported them, serious outcomes such as hospitalization, and year-over-year trends. A FAERS report does not prove the drug caused the effect, and report volume tracks how widely a drug is used, not how likely an effect is for any one person. Educational information, not medical advice.

Total Reports

2,477

Reports Mentioning Death

106

4.3% of reports — not proof the medicine caused the death

Hospitalizations

635

25.6% of reports

Top Indication

Product Used For Unknown Indication

Most Reported Adverse Reactions

DIARRHOEA
358
NAUSEA
221
FATIGUE
210
HEADACHE
136
VOMITING
125
PAIN
118
WEIGHT DECREASED
112
ASTHENIA
111
DIZZINESS
109
ARTHRALGIA
106
DYSPNOEA
101
CROHN^S DISEASE
96
MALAISE
94
PRODUCT PHYSICAL ISSUE
89
ABDOMINAL PAIN
87
PNEUMONIA
87
ABDOMINAL PAIN UPPER
86
CONDITION AGGRAVATED
85

Who Reports Side Effects

Gender Distribution

Female 1,551 (68%)
Male 716 (32%)
Unknown 4

Age Distribution

0-17 7 (0%)
18-44 235 (17%)
45-64 518 (37%)
65-74 387 (27%)
75+ 268 (19%)

Reporting Trend by Year

2004 2025

Reactions in Death Reports

Top reactions reported in 106 reports where death was an outcome. These are voluntarily reported and do not establish causation.

Reaction Reports
DEATH 48
NAUSEA 13
ASTHENIA 10
DIARRHOEA 9
DYSPNOEA 9
RENAL FAILURE 9
ANXIETY 8
ACUTE KIDNEY INJURY 7
DEHYDRATION 7
FATIGUE 7
MYOCARDIAL INFARCTION 7
CARDIAC FAILURE CONGESTIVE 6
DEMENTIA ALZHEIMER^S TYPE 6
PNEUMONIA 6
VOMITING 6
ANAEMIA 5
ARRHYTHMIA 5
ATRIAL FIBRILLATION 5
BLOOD SODIUM DECREASED 5

Reactions in Hospitalization Reports

Top reactions in 635 reports where hospitalization was an outcome.

Reaction Reports
DIARRHOEA 121
NAUSEA 96
FATIGUE 77
VOMITING 68
PNEUMONIA 61
WEIGHT DECREASED 56
ASTHENIA 53
DEHYDRATION 49
DYSPNOEA 49
PAIN 47
FALL 46
ABDOMINAL PAIN 40
DIZZINESS 39
URINARY TRACT INFECTION 38
INTESTINAL OBSTRUCTION 37
HEADACHE 36
PYREXIA 35
BACK PAIN 34

Compare colestipol vs alirocumab →

What the FAERS Data Reveals About colestipol Side Effects

The FDA Adverse Event Reporting System (FAERS) contains 2,477 voluntary reports linked to colestipol and its brand equivalents (Colestid), spanning 2004 through 2025. Of those, 106 (4.3%) listed death as an outcome and 635 (25.6%) involved hospitalization. The most common indication reported alongside adverse events was Product Used For Unknown Indication.

Demographic breakdowns help contextualize who is being exposed to the drug. Of reports with known sex, 68% were female and 32% male; age distribution skews toward 45-64, with 518 reports in that bracket. The single most reported reaction is diarrhoea with 358 submissions, followed by nausea and fatigue.

How to read these numbers

FAERS is a signal-detection tool, not a scorecard. Reports are voluntary, and a single case may list multiple suspect drugs, so numbers above should not be read as incidence rates or per-patient risk. Widely prescribed drugs naturally accumulate more reports than niche therapies even when individual risk is low. These aggregates are useful for spotting patterns that merit further pharmacovigilance, not for choosing between medications. This page is for educational reference only and is not medical advice, speak with a licensed clinician about any side-effect concerns.